That all changed over the past year with the approval of Yervoy™ and Zelboraf™. In this issue of The Melanoma Letter, Dr. Paul Chapman discusses the exciting, newly FDA-approved drug Zelboraf ...

Vemurafenib (Zelboraf™) was the second drug approved for metastatic melanoma this year. In March, the FDA approved ipilimumab (Yervoy™), a monoclonal antibody that binds to CTLA-4, which ...

Healthcare investor David Miller believes Roche will likely acquire Exelixis in order to capture the full economics of the cancer drug cobimetinib. Healthcare investor David Miller believes Roche ...

Plexxikon had great expectations for Zelboraf when it first reached the market, pegging peak sales at around $700 million a year, but it never reached those heights with annual sales in the region ...

While still in the roll-out phase, Mektovi and Braftovi almost doubled survival compared to Roche’s Zelboraf (vemurafenib) in a pivotal trial of melanoma with BRAF mutations, giving the ...

Cancer Research UK, The University of Manchester and Roche Products Ltd (‘Roche’), today (Wednesday 23rd), announce that they have opened a multi-drug, precision medicine trial for people with rare ...

The targeted drug imatinib, or Gleevec, has led to an 80 per cent drop in the number of people who die from chronic myeloid leukaemia, while vemurafenib, or Zelboraf, which the ICR and The Royal ...

this infrastructure award supports a network of 18 adult centres (of excellence) and 11 paediatric locations throughout the UK. *****Combination treatments Cotellic + Zelboraf and Herceptin + Perjeta.